BAE Systems Buys U.K. Drone Specialist
By Christian Moess Laursen
BAE Systems has bought Malloy Aeronautics, a heavy-lift drone specialist for an undisclosed sum, to advance the development of drones capable of delivering heavy supply or evacuating troops.
The defense-and-aerospace group said late Friday that the two U.K. companies--which have been working together since 2021--are developing an all-electric, heavy-lift drone, capable of carrying up to 300 kilograms, as a potential solution to deliver low-cost, rapid-response capability to military, security and civilian customers.
"Our acquisition of Malloy Aeronautics is part of our ongoing strategy to develop and invest in breakthrough technologies," said Simon Barnes, BAE Systems' managing director, air.
Malloy's around 80 employees will continue to operate from its site in Berkshire, U.K.
It will be part of FalconWorks, part of BAE Systems Air's research and development business.
Write to Christian Moess Laursen at christian.moess@wsj.com
(END) Dow Jones Newswires
February 02, 2024 13:09 ET (18:09 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track